<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: significant future payments under", fill: "#87a96b"},
{source: "2: significant future payments under", target: "2: future collaborative", fill: "#87a96b"},
{source: "2: future collaborative", target: "2: agreements", fill: "#87a96b"},
{source: "2: agreements", target: "2: significant investments", fill: "#87a96b"},
{source: "2: significant investments", target: "2: development", fill: "#87a96b"},
{source: "2: development", target: "2: will incur significant selling", fill: "#87a96b"},
{source: "2: will incur significant selling", target: "2: administrative expenses", fill: "#87a96b"},
{source: "2: administrative expenses", target: "2: researching", fill: "#87a96b"},
{source: "2: researching", target: "2: commercializing", fill: "#87a96b"},
{source: "2: commercializing", target: "2: product candidates", fill: "#87a96b"},
{source: "2: significant future payments under", target: "5: depends primarily upon", fill: "#663854"},
{source: "5: depends primarily upon", target: "5: commercialize", fill: "#663854"},
{source: "5: commercialize", target: "5: drug candidates successfully", fill: "#663854"},
{source: "5: depends primarily upon", target: "6: candidates", fill: "#ffdead"},
{source: "6: candidates", target: "6: various stages", fill: "#ffdead"},
{source: "6: various stages", target: "6: development", fill: "#ffdead"},
{source: "6: candidates", target: "7: drug candidates must", fill: "#d0f0c0"},
{source: "7: drug candidates must", target: "7: approved by", fill: "#d0f0c0"},
{source: "7: approved by", target: "7: regulatory authorities", fill: "#d0f0c0"},
{source: "7: drug candidates must", target: "9: drug candidates may", fill: "#808080"},
{source: "9: drug candidates may", target: "9: improvement over existing comparable", fill: "#808080"},
{source: "9: improvement over existing comparable", target: "9: effective", fill: "#808080"},
{source: "9: effective", target: "9: clinical trials", fill: "#808080"},
{source: "9: clinical trials", target: "9: meet applicable regulatory standards", fill: "#808080"},
{source: "9: meet applicable regulatory standards", target: "9: commercial quantities at", fill: "#808080"},
{source: "9: commercial quantities at", target: "9: commercial sale", fill: "#808080"},
{source: "9: commercial sale", target: "9: successfully commercialized", fill: "#808080"},
{source: "9: drug candidates may", target: "12: Furthermore ", fill: "#c0c0c0"},
{source: "12: Furthermore ", target: "12: clinical trials may", fill: "#c0c0c0"},
{source: "12: clinical trials may", target: "12: regulatory authorities", fill: "#c0c0c0"},
{source: "12: regulatory authorities", target: "12: drug candidate", fill: "#c0c0c0"},
{source: "12: Furthermore ", target: "15: candidates", fill: "#ffdab9"},
{source: "15: candidates", target: "15: governmental", fill: "#ffdab9"},
{source: "15: governmental", target: "15: regulations", fill: "#ffdab9"},
{source: "15: regulations", target: "15: development clinical trials manufacturing", fill: "#ffdab9"},
{source: "15: development clinical trials manufacturing", target: "15: commercialization", fill: "#ffdab9"},
{source: "15: candidates", target: "18: drug candidates", fill: "#8c92ac"},
{source: "18: drug candidates", target: "START_HERE", fill: "#8c92ac"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_discovery">Drug discovery</a></td>
      <td>In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_development">Drug development</a></td>
      <td>Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.  It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_design">Drug design</a></td>
      <td>Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preregistration_(science)">Preregistration (science)</a></td>
      <td>Preregistration is the practice of registering the hypotheses, methods, and/or analyses of a scientific study before it is conducted. This can include analyzing primary data or secondary data.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Analysis_of_clinical_trials">Analysis of clinical trials</a></td>
      <td>The analysis of clinical trials involves many related topics including:\n\nthe choice of an estimand (measure of effect size) of interest that is closely linked to the objectives of the trial,\nthe choice and definition of analysis sets,\nthe choice of an appropriate statistical model for the type of data being studied,\nappropriate accounting for the treatment assignment process,\nhandling of missing data,\nhandling of multiple comparisons or endpoints,\naccounting for interim analyses and trial adaptations,\nand appropriate data presentation.One basic guidance document on this topic is the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance E9.\n\n\n== Choice of analysis set ==\nFailure to include all participants in the analysis may bias the trial results.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mirati_Therapeutics">Mirati Therapeutics</a></td>
      <td>Mirati Therapeutics is an American targeted oncology company that focuses on the development of cancer therapeutics.\n\n\n== History ==\nMirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/COVID-19_drug_development">COVID-19 drug development</a></td>
      <td>COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research (506 total candidates in April 2021), with 419 potential COVID-19 drugs in clinical trials, as of April 2021.As early as March 2020, the World Health Organization (WHO), European Medicines Agency (EMA), US Food and Drug Administration (FDA), and the Chinese government and drug manufacturers were coordinating with academic and industry researchers to speed development of vaccines, antiviral drugs, and post-infection therapies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_metabolism">Drug metabolism</a></td>
      <td>Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism (from the Greek xenos "stranger"  and biotic "related to living beings") is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug or poison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Santaris_Pharma">Santaris Pharma</a></td>
      <td>Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>VERTEX PHARMACEUTICALS INC / MA      Item 1A   <font color="blue">Risk Factors   </font>30     ITEM 1A RISK FACTORS          WE EXPECT TO INCUR FUTURE LOSSES AND WE MAY NEVER BECOME PROFITABLE                We have incurred <font color="blue">significant</font> operating losses each year since our     inception and expect to incur a <font color="blue">significant</font> operating loss in 2006</td>
    </tr>
    <tr>
      <td>We     believe that operating <font color="blue">losses will</font> continue beyond 2006, even if we receive     <font color="blue">significant</font> future payments under our existing and <font color="blue">future <font color="blue">collaborative</font></font>     <font color="blue">agreements</font>, because we are planning to make <font color="blue">significant</font> <font color="blue">investment</font>s in     research and <font color="blue">development</font>, and because we will incur <font color="blue">significant</font> selling,     general and <font color="blue"><font color="blue">administrative</font> expenses</font> in the course of <font color="blue">researching</font>, developing     and <font color="blue">commercializing</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">losses will</font>     fluctuate  from  quarter  to  quarter  and year to year, and that such     <font color="blue">fluctuations may</font> be substantial</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> when we will become     profitable, if at all</td>
    </tr>
    <tr>
      <td>MANY OF OUR DRUG CANDIDATES ARE STILL IN THE EARLY STAGES OF DEVELOPMENT AND     ALL OF OUR DRUG CANDIDATES REMAIN SUBJECT TO CLINICAL TESTING AND REGULATORY     APPROVAL  IF  WE ARE UNABLE TO SUCCESSFULLY DEVELOP AND TEST OUR DRUG     CANDIDATES, WE WILL NOT BE SUCCESSFUL                The success of our business <font color="blue">depends primarily upon</font> our ability to     develop  and  <font color="blue">commercialize</font> our <font color="blue">drug <font color="blue">candidates</font> <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>Our drug     <font color="blue">candidates</font> are in <font color="blue">various stages</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our drug <font color="blue">candidates</font> must     satisfy  rigorous  standards of safety and efficacy before they can be     <font color="blue">approved by</font> the FDA or other <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> for sale</td>
    </tr>
    <tr>
      <td>To satisfy     these standards, we must engage in expensive and <font color="blue">lengthy testing</font> of our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Despite our efforts, our drug <font color="blue">candidates</font> may not:          •                 offer <font color="blue">therapeutic</font> or other <font color="blue">improvement over existing comparable</font>                 drugs;          •                 be proven safe and <font color="blue">effective</font> in <font color="blue"><font color="blue">clinical trial</font>s</font>;          •                 <font color="blue">meet applicable <font color="blue">regulatory</font> standards</font>;          •                 be  capable  of being produced in <font color="blue">commercial quantities at</font>                 acceptable costs; or          •                 if approved for <font color="blue">commercial sale</font>, be <font color="blue">successfully</font> <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>Positive results in <font color="blue">preclinical studies</font> of a <font color="blue"><font color="blue">drug candidate</font> may</font> not     be predictive of similar results in humans during <font color="blue"><font color="blue">clinical trial</font>s</font>, and     promising results from early <font color="blue"><font color="blue">clinical trial</font>s</font> of a <font color="blue"><font color="blue">drug candidate</font> may</font> not be     replicated  in  later <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Findings </font>in nonclinical studies     conducted <font color="blue">concurrently</font> with <font color="blue"><font color="blue">clinical trial</font>s</font> could result in abrupt changes     in  our  <font color="blue">development</font>  <font color="blue">activities</font>,  including the possible cessation of     <font color="blue">development</font>  <font color="blue">activities</font> associated with a <font color="blue">drug candidate</font></td>
    </tr>
    <tr>
      <td>Furthermore,     results from our <font color="blue"><font color="blue">clinical trial</font>s</font> may not meet the level of statistical     significance  required  by the FDA or other <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> for     approval of a <font color="blue">drug candidate</font></td>
    </tr>
    <tr>
      <td>A  number of companies in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     <font color="blue">industries</font> have suffered <font color="blue">significant</font> setbacks in late stage <font color="blue"><font color="blue">clinical trial</font>s</font>     even  after  achieving  promising  results in early stage <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Accordingly, the results from the completed <font color="blue">preclinical studies</font> and clinical     trials  and ongoing <font color="blue"><font color="blue">clinical trial</font>s</font> for our drug <font color="blue">candidates</font> may not be     predictive of the results we may obtain in <font color="blue">later stage trials</font>, and are not     predictive of the likelihood of approval of a <font color="blue">drug candidate</font> for commercial     sale</td>
    </tr>
    <tr>
      <td>IF WE ARE UNABLE TO OBTAIN US AND/OR FOREIGN REGULATORY APPROVAL, WE WILL     BE UNABLE TO COMMERCIALIZE OUR DRUG CANDIDATES                Our  drug  <font color="blue">candidates</font>  are  subject  to extensive <font color="blue"><font color="blue">government</font>al</font>     <font color="blue">regulations</font> relating to their <font color="blue">development</font>, <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">manufacturing</font>     and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Rigorous <font color="blue">preclinical testing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> and     an extensive <font color="blue"><font color="blue">regulatory</font> approval process</font> are required in the <font color="blue"><font color="blue">United States</font>     </font>and  in  most other countries prior to the <font color="blue">commercial sale</font> of our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of these and other <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> is     costly, time consuming, uncertain and subject to <font color="blue">unanticipated delays</font></td>
    </tr>
    <tr>
      <td>It is     possible that none of the drug <font color="blue">candidates</font> we are developing will be approved     for marketing</td>
    </tr>
    <tr>
      <td>We have limited experience in conducting and managing the clinical     <font color="blue">trials <font color="blue">necessary</font></font> to obtain <font color="blue"><font color="blue">regulatory</font> approvals</font>, including <font color="blue">approval by</font> the     FDA The time required to complete <font color="blue"><font color="blue">clinical trial</font>s</font> and for the FDA and other     countries &amp;apos  <font color="blue"><font color="blue"><font color="blue">regulatory</font> review</font> processes</font> is uncertain and typically takes many                                         30       _________________________________________________________________       years</td>
    </tr>
    <tr>
      <td>Our  analysis  of  data obtained <font color="blue">from preclinical</font> and clinical     <font color="blue">activities</font> is subject to <font color="blue">confirmation</font> and <font color="blue">interpretation by <font color="blue">regulatory</font></font>     <font color="blue">authorities</font>, <font color="blue">which could</font> delay, limit or <font color="blue">prevent <font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>We may     also encounter <font color="blue">unanticipated delays</font> or increased costs due to <font color="blue">government</font>     <font color="blue">regulation from future <font color="blue">legislation</font></font> or <font color="blue"><font color="blue">administrative</font> action</font> or changes in     FDA <font color="blue">policy during</font> the period of product <font color="blue">development</font>, <font color="blue"><font color="blue">clinical trial</font>s</font> and FDA     <font color="blue"><font color="blue">regulatory</font> review</font></td>
    </tr>
    <tr>
      <td>Any delay in obtaining or failure to obtain required <font color="blue">approvals could</font>     <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> any     drug  candidate</td>
    </tr>
    <tr>
      <td>Furthermore, any <font color="blue">regulatory</font> approval to market a drug     product may be subject to unexpected <font color="blue">limitations</font> on the indicated uses for     which we may market the <font color="blue">drug product</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">limitations</font> may limit the size     of the market for the <font color="blue">drug product</font></td>
    </tr>
    <tr>
      <td>We are also subject to numerous foreign <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>     governing  the conduct of <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">manufacturing</font> and marketing     authorization, pricing and third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>The foreign <font color="blue">regulatory</font>     approval process includes all of the <font color="blue">risks associated with</font> the FDA approval     <font color="blue">process described</font> above, <font color="blue">as well as risks attributable</font> to the <font color="blue">satisfaction</font>     of <font color="blue">foreign <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>Approval by the FDA does not ensure <font color="blue">approval by</font>     <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Foreign <font color="blue">jurisdictions may</font>     have <font color="blue">different approval procedures than</font> those required by the FDA and may     impose <font color="blue">additional</font> testing <font color="blue">requirements</font> for our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>IF CLINICAL TRIALS FOR OUR DRUG CANDIDATES ARE PROLONGED OR DELAYED, WE MAY     BE UNABLE TO COMMERCIALIZE OUR DRUG CANDIDATES ON A TIMELY BASIS, WHICH     WOULD REQUIRE US TO INCUR ADDITIONAL COSTS AND WOULD DELAY OUR RECEIPT OF     ANY PRODUCT REVENUE                We <font color="blue">cannot predict</font> whether or not we will encounter problems with any     of our completed, ongoing or planned <font color="blue"><font color="blue">clinical trial</font>s</font> that will cause us or     <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> to delay or suspend <font color="blue"><font color="blue">clinical trial</font>s</font>, or delay the     analysis of data from our completed or ongoing <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Any of the     <font color="blue">following could delay</font> the clinical <font color="blue">development</font> of our drug <font color="blue">candidates</font>:          •                 ongoing  <font color="blue">discussions</font>  with  the  FDA or comparable foreign                 <font color="blue">authorities</font>  regarding the scope or design of our clinical                 trials;          •                 delays  in  receiving  or the <font color="blue">inability</font> to obtain required                 <font color="blue">approvals from</font> IRBs or other reviewing entities at clinical                 <font color="blue">sites selected</font> for <font color="blue">participation</font> in our <font color="blue"><font color="blue">clinical trial</font>s</font>;          •                 delays  in <font color="blue">enrolling volunteers</font> and patients into clinical                 trials;          •                 a  lower than anticipated <font color="blue">retention rate</font> of volunteers and                 patients in <font color="blue"><font color="blue">clinical trial</font>s</font>;          •                 the need to repeat <font color="blue"><font color="blue">clinical trial</font>s</font> as a result of <font color="blue">inconclusive</font>                 results or <font color="blue">unforeseen complications</font> in testing;          •                 inadequate  supply  or deficient quality of <font color="blue">drug candidate</font>                 materials or other <font color="blue">materials <font color="blue">necessary</font></font> for the conduct of our                 <font color="blue"><font color="blue">clinical trial</font>s</font>;          •                 unfavorable FDA inspection and review of a <font color="blue"><font color="blue">clinical trial</font> site</font>                 or records of any clinical or <font color="blue">preclinical investigation</font>;          •                 serious and unexpected drug-related side effects experienced by                 <font color="blue">participants</font> in our <font color="blue"><font color="blue">clinical trial</font>s</font>; or          •                 the <font color="blue">placement by</font> the FDA of a clinical hold on a trial</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">enroll patients</font> in our <font color="blue"><font color="blue">clinical trial</font>s</font> in sufficient     numbers  and on a <font color="blue">timely basis will</font> be subject to a number of factors,     including the size of the <font color="blue">patient population</font>, the nature of the protocol,     the proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">availability</font> of <font color="blue">effective</font>     <font color="blue">treatments</font> for the <font color="blue">relevant disease</font> and the <font color="blue">eligibility criteria</font> for the     <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>In addition, subjects may drop out of our <font color="blue"><font color="blue">clinical trial</font>s</font>,     and thereby possibly impair the validity or <font color="blue">statistical significance</font> of the     trials</td>
    </tr>
    <tr>
      <td>Delays in patient <font color="blue">enrollment</font> or unforeseen drop out rates may result     in increased costs and longer <font color="blue">development</font> times</td>
    </tr>
    <tr>
      <td>While all or a portion of     these <font color="blue">additional</font> costs may be <font color="blue">covered by payments under</font> our <font color="blue">collaborative</font>     <font color="blue">agreements</font>, we bear all of the costs for our <font color="blue">development</font> <font color="blue">candidates</font> for     which we have <font color="blue">no financial support from</font> a <font color="blue">collaborator</font></td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________               We, the FDA or other applicable <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> may suspend     <font color="blue"><font color="blue">clinical trial</font>s</font> of a <font color="blue">drug candidate</font> at any time if we or they believe the     subjects or <font color="blue">patients participating</font> in such <font color="blue"><font color="blue">clinical trial</font>s</font> are being exposed     to unacceptable <font color="blue">health risks</font> or for other reasons</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> whether any of our drug <font color="blue">candidates</font> will encounter     problems  during  clinical  trials  which  will cause us or <font color="blue">regulatory</font>     <font color="blue">authorities</font>  to delay or suspend these trials, or <font color="blue">which will delay</font> the     analysis of data from these trials</td>
    </tr>
    <tr>
      <td>In addition, it is impossible to predict     whether legislative changes will be enacted, or whether FDA <font color="blue">regulations</font>,     guidance or <font color="blue">interpretations will</font> be changed, or what the impact of such     changes, if any, may be</td>
    </tr>
    <tr>
      <td>If we experience any <font color="blue">such problems</font>, we may not have     the <font color="blue">financial resources</font> to continue <font color="blue">development</font> of the <font color="blue">drug candidate</font> that     is affected or the <font color="blue">development</font> of any of our other drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>IF OUR PROCESSES AND SYSTEMS ARE NOT COMPLIANT WITH REGULATORY REQUIREMENTS,     WE  COULD  BE  SUBJECT  TO  DELAYS  IN FILING NEW DRUG APPLICATIONS OR     RESTRICTIONS ON MARKETING OF PRODUCTS AFTER THEY HAVE BEEN APPROVED                We currently are developing drug <font color="blue">product <font color="blue">candidates</font></font> for <font color="blue">regulatory</font>     approval for the first time since the Companyapstas inception, and are in the     process of <font color="blue">implementing regulated processes</font> and systems required to obtain     and maintain <font color="blue">regulatory</font> approval for our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Certain of     these processes and systems for conducting <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">manufacturing</font>     material must be compliant with <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> before we can apply     for <font color="blue">regulatory</font> approval for our drug <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>These processes and     <font color="blue">systems will</font> be subject to <font color="blue">continual review</font> and <font color="blue">periodic <font color="blue">inspection by</font></font> the     FDA and other <font color="blue">regulatory</font> bodies</td>
    </tr>
    <tr>
      <td>If we are unable to achieve compliance in a     <font color="blue">timely fashion</font>, we may experience delays in filing for <font color="blue">regulatory</font> approval     for  our  drug <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">later <font color="blue">discovery</font></font> of     <font color="blue">previously unknown problems</font> or <font color="blue">safety issues with <font color="blue">approved products</font></font> or     <font color="blue">manufacturing</font> processes, or failure to <font color="blue">comply with</font> <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>,     may result in <font color="blue"><font color="blue">restrictions</font> on such products</font> or <font color="blue">manufacturing</font> processes,     withdrawal of <font color="blue">products from</font> the market, the imposition of civil or criminal     penalties or a <font color="blue">refusal by</font> the FDA and/or other <font color="blue">regulatory</font> bodies to approve     <font color="blue">pending <font color="blue">application</font>s</font> for <font color="blue">marketing approval</font> of new drugs or <font color="blue">supplements</font> to     <font color="blue">approved <font color="blue">application</font>s</font>, any of <font color="blue">which could</font> have a material adverse effect on     our business</td>
    </tr>
    <tr>
      <td>In addition, we are a party to <font color="blue">collaboration</font> <font color="blue">agreements</font> that     transfer   <font color="blue">responsibility</font>  for  complying  with  specified  <font color="blue">regulatory</font>     <font color="blue">requirements</font>, such as filing and maintenance of <font color="blue">marketing authorizations</font> and     safety reporting, to our <font color="blue">collaborator</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">collaborator</font>s do not fulfill     these <font color="blue">regulatory</font> <font color="blue">obligations</font>, any products for which we or they obtain     <font color="blue">approval may</font> be <font color="blue">withdrawn from</font> the market, which would have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>EVEN IF WE OBTAIN REGULATORY APPROVALS, OUR DRUG CANDIDATES WILL BE SUBJECT     TO ONGOING REGULATORY REVIEW IF WE FAIL TO COMPLY WITH CONTINUING US AND     APPLICABLE FOREIGN REGULATIONS, WE COULD LOSE THOSE APPROVALS, AND OUR     BUSINESS WOULD BE SERIOUSLY HARMED                Even if we receive <font color="blue">regulatory</font> approval of any drug <font color="blue">candidates</font> that     we are developing, we will be subject to continuing <font color="blue"><font color="blue">regulatory</font> review</font>,     including the review of clinical results that are reported after our drug     <font color="blue">candidates</font> become <font color="blue">commercially</font> available, approved drugs</td>
    </tr>
    <tr>
      <td>Since drugs are     more <font color="blue">widely used by patients once approval</font> has been obtained, side effects     and other <font color="blue">problems may</font> be observed after approval that were not seen or     anticipated  during  pre-approval  clinical  trials</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> and the <font color="blue">manufacturing</font> <font color="blue">facilities</font> we engage to make any of our     drug <font color="blue">candidates</font> will also be subject to <font color="blue">periodic review</font> and <font color="blue">inspection by</font>     the FDA The <font color="blue">subsequent <font color="blue">discovery</font></font> of <font color="blue">previously unknown problems</font> with the     drug, <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> or <font color="blue">manufacturing</font> <font color="blue">facilities</font> may result in <font color="blue">restrictions</font>     on the drug, <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> or <font color="blue">facilities</font>, including withdrawal of the drug     from the market or our <font color="blue">inability</font> to use the <font color="blue">facilities</font> to make our drug</td>
    </tr>
    <tr>
      <td>If     we fail to <font color="blue">comply with</font> applicable continuing <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>, we may     be  subject to fines, suspension or withdrawal of <font color="blue">regulatory</font> approval,     product  recalls  and  seizures,  operating  <font color="blue">restrictions</font> and criminal     <font color="blue"><font color="blue">prosecution</font>s</font></td>
    </tr>
    <tr>
      <td>32       _________________________________________________________________       OUR DRUG DEVELOPMENT EFFORTS ARE DATA-DRIVEN AND THEREFORE POTENTIALLY     SUBJECT TO ABRUPT CHANGES IN EXPECTED OUTCOMES                Small molecule <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font> involve, initially,     the  <font color="blue">identification</font>  of  chemical  <font color="blue">compounds which may</font> have <font color="blue">promise as</font>     <font color="blue">treatments</font>  for <font color="blue">specific diseases</font></td>
    </tr>
    <tr>
      <td>Once identified as drug <font color="blue">candidates</font>,     compounds are subjected to years of testing in a <font color="blue">laboratory setting</font>, in     animals and in people</td>
    </tr>
    <tr>
      <td>Our <font color="blue">ultimate objective</font> is to determine whether the     compounds have physical characteristics, both intrinsically and in animal     and <font color="blue">human systems</font> and including a <font color="blue">toxicological profile</font>, that are compatible     with clinical and <font color="blue">commercial success</font> in treatment of the disease being     targeted</td>
    </tr>
    <tr>
      <td><font color="blue">Throughout </font>this process, experiments are conducted and data are     gathered that could reinforce a decision to move to the next step in the     <font color="blue">evaluation</font>  process  for  a particular <font color="blue">drug candidate</font>, could result in     <font color="blue">uncertainty</font>  over  the proper course to pursue, or could result in the     <font color="blue">termination</font> of further drug <font color="blue">development</font> efforts with respect to the compound     being evaluated</td>
    </tr>
    <tr>
      <td>We monitor the results of our <font color="blue"><font color="blue">discovery</font> research</font> and our     nonclinical  studies  and  clinical  trials and <font color="blue">regularly evaluate</font> and     re-evaluate our <font color="blue">portfolio <font color="blue">investment</font>s with</font> the objective of <font color="blue">balancing risk</font>     and  <font color="blue">potential return</font> in view of new data and scientific, business and     <font color="blue">commercial insights</font></td>
    </tr>
    <tr>
      <td>This process can result in <font color="blue"><font color="blue">relatively</font> abrupt</font> changes in     focus and <font color="blue">priority as new</font> information comes to light and we gain <font color="blue">additional</font>     <font color="blue">insights into ongoing programs</font> and <font color="blue">potential new programs</font></td>
    </tr>
    <tr>
      <td>WE DEPEND ON THIRD PARTY MANUFACTURERS AND SUPPLIERS, AND AS A RESULT WE MAY     BE SUBJECT TO MANUFACTURING AND SUPPLY DISRUPTIONS OUTSIDE OF OUR CONTROL                We  expect  that  we  will  need  to <font color="blue">significant</font>ly augment our     <font color="blue">manufacturing</font>,  supply  chain  and <font color="blue">quality assurance resources</font> for our     later-stage drug <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have no experience in <font color="blue">manufacturing</font>     <font color="blue">pharmaceutical</font> products and in conducting <font color="blue">manufacturing</font> testing programs     required to obtain FDA and other <font color="blue"><font color="blue">regulatory</font> approvals</font>, and there can be no     assurance that we will develop those <font color="blue"><font color="blue">capabilities</font> <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>If we are     unable to establish these <font color="blue">capabilities</font>, we may be unable to achieve our     <font color="blue">development</font>  and  <font color="blue">commercialization</font> goals</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently relying on</font>     networks of third party <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> and <font color="blue">suppliers worldwide</font> to synthesize,     tablet, and package our drug <font color="blue">candidates</font> for <font color="blue"><font color="blue">clinical trial</font>s</font> and we expect     that we <font color="blue">will continue</font> to do so to meet our <font color="blue">commercial supply</font> needs for these     products, if they are approved for sale</td>
    </tr>
    <tr>
      <td>As a result of our <font color="blue">reliance on</font>     these third party <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> and suppliers, some of whom currently are     our  sole  source  for  clinical  trial material, we may be subject to     <font color="blue">significant</font>  supply  <font color="blue">disruptions</font>  outside of our control</td>
    </tr>
    <tr>
      <td>These supply     <font color="blue">disruptions</font> may result from a number of factors including shortages in     product  raw  materials,  labor  or technical <font color="blue">difficult</font>ies, <font color="blue">regulatory</font>     <font color="blue">inspections</font> or <font color="blue">restrictions</font>, and shipping and <font color="blue">customs delays</font></td>
    </tr>
    <tr>
      <td>We plan to     identify and <font color="blue">enter into</font> commercial <font color="blue">relationship</font>s with multiple suppliers of     the  materials and <font color="blue">manufacturing</font> services <font color="blue">necessary</font> for the synthesis,     tableting and packaging of our drug <font color="blue">candidates</font> and, if approved for sale,     our drugs</td>
    </tr>
    <tr>
      <td>We expect that this <font color="blue">approach will reduce</font> our risk of supply chain     <font color="blue">disruptions</font> by reducing our <font color="blue">reliance on</font> any <font color="blue">one <font color="blue"><font color="blue">manufacture</font>r</font></font> or supplier,     but  we <font color="blue">will remain vulnerable</font> to <font color="blue">disruptions</font> arising <font color="blue">from performance</font>     <font color="blue">failure by</font> a vendor in our <font color="blue">manufacturing</font> supply chain, particularly if we     are unable to <font color="blue">secure second sources</font> for <font color="blue"><font color="blue">necessary</font> products</font> and services</td>
    </tr>
    <tr>
      <td>Any     supply <font color="blue">disruptions</font> could impact the timing of our <font color="blue"><font color="blue">clinical trial</font>s</font> and the     <font color="blue">commercial launch</font> of any approved <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>Furthermore, we     may  be  required  to  modify  our  <font color="blue">production methods</font> to <font color="blue">permit us</font> to     <font color="blue">economically <font color="blue">manufacture</font></font> our products for <font color="blue">commercial launch</font> and sale</td>
    </tr>
    <tr>
      <td><font color="blue">Upon     </font>approval of a <font color="blue">pharmaceutical</font> product for sale, if any, we <font color="blue">similarly may</font> be     at risk of <font color="blue">supply chain disruption</font> for our <font color="blue">commercial drug supply</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">modifications may</font> require us to reevaluate our resources and the resources     of our third party <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> and suppliers, <font color="blue">which could</font> result in abrupt     changes in our <font color="blue">production methods</font> and supplies</td>
    </tr>
    <tr>
      <td>The production of our drug     <font color="blue">candidates</font> is based in part <font color="blue">on <font color="blue">technology</font></font> that we believe to be <font color="blue">proprietary</font></td>
    </tr>
    <tr>
      <td>We have licensed this <font color="blue">technology</font> to enable our third party <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> and     suppliers to <font color="blue">manufacture</font> drug <font color="blue">candidates</font> for us</td>
    </tr>
    <tr>
      <td>However, in the course of     their services, a <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font> may</font> develop process <font color="blue">technology</font>     related to the <font color="blue">manufacture</font> of our drug <font color="blue">candidates</font> that the <font color="blue"><font color="blue">manufacture</font>r</font>     owns, <font color="blue">either independently</font> or <font color="blue">jointly with us</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">would increase</font> our     <font color="blue">reliance on</font> that <font color="blue"><font color="blue">manufacture</font>r</font> or require us to obtain a <font color="blue">license from</font> that     <font color="blue"><font color="blue">manufacture</font>r</font> in order to have our <font color="blue">products <font color="blue">manufacture</font>d by</font> other suppliers     utilizing the <font color="blue">same process</font></td>
    </tr>
    <tr>
      <td>33       _________________________________________________________________       WE RELY ON THIRD PARTIES TO CONDUCT OUR CLINICAL TRIALS, AND THOSE THIRD     PARTIES  MAY  NOT  PERFORM  SATISFACTORILY,  INCLUDING FAILING TO MEET     ESTABLISHED DEADLINES FOR THE COMPLETION OF SUCH TRIALS                We do not have the ability to independently conduct <font color="blue"><font color="blue">clinical trial</font>s</font>     for our drug <font color="blue">candidates</font>, and we <font color="blue">rely on <font color="blue">third parties</font> such as contract</font>     research <font color="blue"><font color="blue">organization</font>s</font>, medical institutions and <font color="blue">clinical investigators</font> to     <font color="blue">enroll qualified patients</font> and conduct our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font>     these <font color="blue">third parties</font> for clinical <font color="blue">development</font> <font color="blue">activities</font> reduces our control     over these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Accordingly, these third-party contractors may not     complete <font color="blue">activities</font> on schedule, or may not conduct our <font color="blue"><font color="blue">clinical trial</font>s</font> in     accordance with <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> or our <font color="blue">trial design</font></td>
    </tr>
    <tr>
      <td>To date, we     believe our <font color="blue">contract research <font color="blue"><font color="blue">organization</font>s</font></font> and other similar <font color="blue">entities with</font>     which we are working <font color="blue">generally</font> have performed well</td>
    </tr>
    <tr>
      <td>However, if these third     parties do not <font color="blue">successfully</font> carry out their <font color="blue"><font color="blue">contractual</font> duties</font> or meet     expected <font color="blue">deadlines</font>, we may be required to <font color="blue">replace them</font></td>
    </tr>
    <tr>
      <td>Although we believe     that there are a number of other third-party contractors we could engage to     continue these <font color="blue">activities</font>, it may result in a delay of the <font color="blue">affected trial</font></td>
    </tr>
    <tr>
      <td>Accordingly,  our  efforts  to  obtain  <font color="blue">regulatory</font>  approvals  for and     <font color="blue">commercialize</font> our drug <font color="blue">candidates</font> may be delayed</td>
    </tr>
    <tr>
      <td>OUR SALES AND MARKETING EXPERIENCE IS LIMITED                We have limited experience in marketing and selling <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>We must either develop a marketing and <font color="blue">sales force</font> or <font color="blue">enter into</font>     <font color="blue">arrangements</font>  with <font color="blue">third parties</font> to market and sell any of our product     <font color="blue">candidates</font> that are <font color="blue">approved by</font> <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>We do not know     whether we will be able to <font color="blue">enter into</font> marketing and sales <font color="blue">agreements</font> with     others on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font>     develop our own sales and marketing force for drug <font color="blue">candidates</font> for which we     have  retained marketing or co-promotion rights</td>
    </tr>
    <tr>
      <td>As we develop our own     marketing and sales capability, we may be <font color="blue">competing with</font> other companies     that  currently  have  experienced and well-funded marketing and sales     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">granted exclusive <font color="blue">marketing rights</font></font> for Lexiva/Telzir,     <font color="blue">brecanavir</font> (VX-385) and VX-409 to <font color="blue">GlaxoSmithKline </font>worldwide (except for     <font color="blue">brecanavir</font> in the Far East where we have retained rights), and for VX-680     and  VX-667  to Merck</td>
    </tr>
    <tr>
      <td><font color="blue">Avalon Pharmaceuticals </font>has exclusive, worldwide     <font color="blue">marketing rights</font> to VX-944</td>
    </tr>
    <tr>
      <td><font color="blue">Mitsubishi </font>has exclusive <font color="blue">marketing rights</font> to     VX-950 in Japan and certain Far East countries</td>
    </tr>
    <tr>
      <td>Even though we retain some co-promotion rights in some     <font color="blue"><font color="blue">collaboration</font>s</font>, to the extent that our <font color="blue">collaborator</font>s have <font color="blue">commercial rights</font>     to our products, any revenues we receive from those <font color="blue"><font color="blue">products will</font> depend</font>     <font color="blue">primarily on</font> the sales and <font color="blue">marketing efforts</font> of others</td>
    </tr>
    <tr>
      <td>WE MAY NEED TO RAISE ADDITIONAL CAPITAL THAT MAY NOT BE AVAILABLE                We expect to incur substantial research and <font color="blue">development</font> and related     <font color="blue">supporting expenses as</font> we design and develop existing and <font color="blue">future compounds</font>,     undertake <font color="blue"><font color="blue">clinical trial</font>s</font> of drug <font color="blue">candidates</font> resulting <font color="blue">from such compounds</font>,     and  build  our  <font color="blue">manufacturing</font>, <font color="blue">regulatory</font>, <font color="blue">development</font> and commercial     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We  also expect to incur substantial <font color="blue">administrative</font> and     <font color="blue">commercialization</font>  <font color="blue">expenditures</font> in the future and substantial expenses     related to the filing, <font color="blue">prosecution</font>, defense and <font color="blue">enforcement</font> of patent and     other <font color="blue"><font color="blue">intellectual</font> property</font> claims</td>
    </tr>
    <tr>
      <td>We may need to make <font color="blue">significant</font> capital     <font color="blue">investment</font> in building our <font color="blue">manufacturing</font> capacity and creating pre-launch     inventory for one or more of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We anticipate that we     will finance these substantial cash needs with:          •                 cash received from our existing <font color="blue">collaborative</font> <font color="blue">agreements</font>;          •                 cash received from new <font color="blue">collaborative</font> <font color="blue">agreements</font>;          •                 Lexiva/Telzir <font color="blue">royalty revenue</font>;          •                 existing cash reserves, together with interest earned on those                 reserves; and          •                 <font color="blue">future product sales</font> to the extent that we <font color="blue">market products</font>                 directly</td>
    </tr>
    <tr>
      <td>34       _________________________________________________________________               We expect that funds from these <font color="blue">sources will</font> be sufficient to fund     our planned <font color="blue">activities</font> for at least the <font color="blue">next eighteen months from</font> the date     of this filing</td>
    </tr>
    <tr>
      <td>If not, it will be <font color="blue">necessary</font> to raise <font color="blue">additional</font> funds     <font color="blue">through public offerings</font> or <font color="blue">private placements</font> of equity or <font color="blue">debt securities</font>     or  other  methods  of  financing</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">financial resources</font> are     sufficient  to meet our short or <font color="blue">intermediate term</font> needs, we may still     decide, as we have in the past, to raise <font color="blue">additional</font> funds when we believe     <font color="blue">financial market <font color="blue">conditions</font></font> are favorable</td>
    </tr>
    <tr>
      <td>Any <font color="blue">equity financings could</font>     result  in  dilution  to  our then-existing <font color="blue">security holders</font></td>
    </tr>
    <tr>
      <td>Any debt     financing, if <font color="blue">available at</font> all, may be on terms that, among other things,     restrict our ability to <font color="blue">pay dividends</font> and interest (although we do not     intend to <font color="blue">pay dividends</font> for the <font color="blue">foreseeable future</font>)</td>
    </tr>
    <tr>
      <td>The required interest     <font color="blue">payments associated with</font> any <font color="blue">significant</font> <font color="blue">additional</font> debt financing could     <font color="blue">materially</font>  <font color="blue">adversely</font>  affect  our  ability to service our convertible     subordinated notes and <font color="blue">convertible senior subordinated</font> notes</td>
    </tr>
    <tr>
      <td>The terms of     any  <font color="blue">additional</font>  debt <font color="blue">financing may</font> also, under certain circumstances,     restrict or <font color="blue">prohibit us from</font> making <font color="blue">interest payments on</font> our convertible     subordinated notes and <font color="blue">convertible senior subordinated</font> notes</td>
    </tr>
    <tr>
      <td>If adequate     funds are not available, we may be required to curtail <font color="blue">significant</font>ly or     <font color="blue">discontinue one</font> or more of our research, <font color="blue">drug <font color="blue">discovery</font></font> or <font color="blue">development</font>     programs (including <font color="blue"><font color="blue">clinical trial</font>s</font>), or attempt to obtain <font color="blue">funds through</font>     <font color="blue">arrangements</font> with <font color="blue">collaborator</font>s or others that may require us to <font color="blue">relinquish</font>     rights  to  certain  of  our  <font color="blue">technologies</font>  or products in research or     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">financing may</font> not be <font color="blue">available on</font> acceptable terms,     if at all</td>
    </tr>
    <tr>
      <td>IF WE ARE UNABLE TO ATTRACT AND RETAIN COLLABORATORS FOR RESEARCH SUPPORT     AND THE DEVELOPMENT AND COMMERCIALIZATION OF OUR PRODUCTS, WE MAY NOT BE     ABLE TO FUND OUR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES                Our research, <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">collaborator</font>s have     agreed to <font color="blue">fund portions</font> of our research and <font color="blue">development</font> programs and/or to     conduct  the  <font color="blue">development</font>  and  <font color="blue">commercialization</font> of <font color="blue">specified product</font>     <font color="blue">candidates</font> and, if they are approved, products</td>
    </tr>
    <tr>
      <td>In exchange, we have given     them <font color="blue">technology</font>, product and <font color="blue">marketing rights</font> relating to those products</td>
    </tr>
    <tr>
      <td>Some of our corporate <font color="blue">collaborator</font>s have rights to control the planning and     execution of product <font color="blue">development</font> and clinical programs</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborator</font>s     <font color="blue">may exercise</font> their <font color="blue">control rights</font> in ways that <font color="blue">may negatively affect</font> the     timing and success of those programs</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaboration</font>s</font> are subject to     <font color="blue">termination</font> rights by the <font color="blue">collaborator</font>s</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">collaborator</font>s were to     terminate  its  <font color="blue">relationship</font>  with us, or fail to meet its <font color="blue">contractual</font>     <font color="blue">obligations</font>, that <font color="blue">action could</font> have a material adverse effect on our ability     to undertake research, to fund related and other programs and to develop,     <font color="blue">manufacture</font>  and  market  any products that may have resulted from the     <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>We expect to seek <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">arrangements</font>,     which may not be available to us, to <font color="blue">provide research support</font> and to develop     and <font color="blue">commercialize</font> our products in the future</td>
    </tr>
    <tr>
      <td>For example, a <font color="blue">significant</font>     portion of our <font color="blue">overall research effort</font> is <font color="blue">conducted under</font> our research     <font color="blue"><font color="blue">collaboration</font>s</font> with Novartis and Merck, both of which are scheduled to     conclude  in  the  first  half of 2006</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">enter into</font>     <font color="blue">collaborative</font> <font color="blue">arrangements</font> that <font color="blue">would extend</font> or replace these research     <font color="blue"><font color="blue">collaboration</font>s</font>, or to find other means of financing the <font color="blue">effort currently</font>     devoted to these <font color="blue">research programs</font>, our ability to conduct our research,     <font color="blue">development</font> and commercial <font color="blue">activities</font> could be <font color="blue">adversely</font> affected to a     material  degree</td>
    </tr>
    <tr>
      <td><font color="blue">Similarly </font>we may choose to <font color="blue">enter into</font> <font color="blue">collaborative</font>     <font color="blue">arrangements</font> to advance the <font color="blue">development</font> of some of our preclinical and     clinical <font color="blue">development</font> stage compounds</td>
    </tr>
    <tr>
      <td>Even if we are able to establish     acceptable  <font color="blue">collaborative</font>  <font color="blue">arrangements</font> in the future, they may not be     successful</td>
    </tr>
    <tr>
      <td>IF OUR COMPETITORS BRING SUPERIOR PRODUCTS TO MARKET OR BRING THEIR PRODUCTS     TO MARKET BEFORE WE DO, WE MAY BE UNABLE TO FIND A MARKET FOR OUR PRODUCTS                Our products in <font color="blue">development</font> may not be able to compete <font color="blue">effective</font>ly     <font color="blue">with products</font> that are <font color="blue">currently on</font> the market or <font color="blue">new products</font> that may be     developed by others</td>
    </tr>
    <tr>
      <td>There are many other companies developing products for     the  <font color="blue">same indications</font> that we are pursuing in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In order to     compete <font color="blue">successfully</font> in these areas, we <font color="blue">must <font color="blue">demonstrate</font> improved safety</font>,     efficacy and ease of                                         35       _________________________________________________________________       <font color="blue">manufacturing</font> and <font color="blue">gain <font color="blue">market acceptance</font> over competing products</font> that may     receive <font color="blue">regulatory</font> approval before or after our products, and over those     that  currently are marketed</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font>, including major     <font color="blue">pharmaceutical</font> <font color="blue">companies such as</font> GlaxoSmithKline, Merck, Roche, Amgen,     Boerhinger  Ingelheim, Novartis, Johnson &amp; Johnson and Schering-Plough     possess substantially greater financial, technical and <font color="blue">human <font color="blue">resources than</font></font>     we possess</td>
    </tr>
    <tr>
      <td>In addition, many of our <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater     experience than we have in <font color="blue">conducting preclinical</font> and <font color="blue">nonclinical testing</font>     and  human  <font color="blue"><font color="blue">clinical trial</font>s</font> of new <font color="blue">pharmaceutical</font> products, scaling up     <font color="blue">manufacturing</font> <font color="blue">operations</font> and obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font> of products and     <font color="blue">manufacturing</font>  <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may succeed in     obtaining <font color="blue">regulatory</font> approval for products more <font color="blue">rapidly than</font> we do</td>
    </tr>
    <tr>
      <td>If we     obtain <font color="blue">regulatory</font> approval and launch <font color="blue">commercial sale</font>s of our products, we     <font color="blue">also will <font color="blue">compete with</font> respect</font> to <font color="blue">manufacturing</font> efficiency and sales and     marketing <font color="blue">capabilities</font>, areas in which we currently have limited experience</td>
    </tr>
    <tr>
      <td>IF WE FAIL TO EXPAND OUR HUMAN RESOURCES AND MANAGE OUR GROWTH EFFECTIVELY,     OUR BUSINESS MAY SUFFER                We expect that if our clinical <font color="blue">candidates</font> continue to progress in     <font color="blue">development</font>, we continue to build our <font color="blue">commercial <font color="blue">organization</font></font> and our drug     <font color="blue"><font color="blue">discovery</font> efforts continue</font> to generate drug <font color="blue">candidates</font>, we will require     <font color="blue">significant</font> <font color="blue">additional</font> <font color="blue">investment</font> in personnel, <font color="blue">management</font> systems and     resources</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our products, achieve our research     and  <font color="blue">development</font>  <font color="blue">objectives</font>,  and  satisfy  our <font color="blue">commitments under</font> our     <font color="blue">collaboration</font> <font color="blue">agreements</font> depends on our ability to respond <font color="blue">effective</font>ly to     these demands and expand our <font color="blue">internal <font color="blue">organization</font></font> to accommodate <font color="blue">additional</font>     anticipated growth</td>
    </tr>
    <tr>
      <td>If we are unable to manage our growth <font color="blue">effective</font>ly, there     could be a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>IF WE LOSE OUR TECHNOLOGICAL ADVANTAGES, WE MAY NOT BE ABLE TO COMPETE IN     THE MARKETPLACE                We believe that our integrated <font color="blue">drug <font color="blue">discovery</font></font> capability gives us a     <font color="blue"><font color="blue">technological</font> advantage over</font> our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>However, the <font color="blue">pharmaceutical</font>     research field is <font color="blue">characterized</font> by rapid <font color="blue">technological</font> progress and intense     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>As a result, we may not realize the expected benefits from     these  <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>For example, a large <font color="blue">pharmaceutical</font> company, with     <font color="blue">significant</font>ly  more  <font color="blue">resources than</font> we have, <font color="blue">could pursue</font> a systematic     approach to the <font color="blue">discovery</font> of drugs based on gene families, using <font color="blue">proprietary</font>     <font color="blue">drug target</font>s, compound libraries, novel chemical approaches, structural     <font color="blue">protein analysis</font> and information <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Such a company might identify     broadly applicable compound classes faster and more <font color="blue">effective</font>ly than we do</td>
    </tr>
    <tr>
      <td>Further, we believe that interest in the <font color="blue">application</font> of structure-based drug     design, parallel drug design and related approaches has <font color="blue"><font color="blue">accelerate</font>d as</font> the     strategies  have  become  more widely understood</td>
    </tr>
    <tr>
      <td>Businesses, academic     institutions, <font color="blue"><font color="blue">government</font>al</font> agencies and other public and <font color="blue">private research</font>     <font color="blue"><font color="blue">organization</font>s</font> are <font color="blue">conducting research</font> to develop <font color="blue">technologies</font> that may     <font color="blue">compete with</font> those we use</td>
    </tr>
    <tr>
      <td>It is possible that our <font color="blue">competitors</font> could acquire     or  develop  <font color="blue">technologies</font> that would render our <font color="blue">technology</font> obsolete or     <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>For  example,  a <font color="blue">competitor could</font> develop information     <font color="blue">technologies</font>  that  <font color="blue">accelerate</font>  the atomic-level analysis of potential     compounds that bind to the <font color="blue">active site</font> of a <font color="blue">drug target</font>, and predict the     absorption, toxicity, and relative ease-of-synthesis of <font color="blue">candidate compounds</font></td>
    </tr>
    <tr>
      <td>If we were unable to access the same <font color="blue">technologies</font> at an acceptable price,     our business could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>THE LOSS OF THE SERVICES OF KEY EMPLOYEES OR THE FAILURE TO HIRE QUALIFIED     EMPLOYEES WOULD NEGATIVELY IMPACT OUR BUSINESS AND FUTURE GROWTH                Because our product <font color="blue">discovery</font> and <font color="blue">development</font> <font color="blue">activities</font> are highly     technical in nature, we require the services of <font color="blue">highly qualified</font> and trained     <font color="blue">scientists</font> who have the skills <font color="blue">necessary</font> to conduct these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">future <font color="blue">success will depend</font></font> in large part on the <font color="blue">continued services</font> of our     <font color="blue">key scientific</font> and <font color="blue"><font color="blue">management</font> personnel</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into <font color="blue">employment</font></font>     <font color="blue">agreements</font> with some <font color="blue">individuals</font> and provide compensation-related benefits     to all of our <font color="blue">key employees</font> that vest over time and <font color="blue">therefore induce them</font> to     <font color="blue">remain with us</font></td>
    </tr>
    <tr>
      <td>However, the <font color="blue">employment</font> <font color="blue">agreements</font> can be terminated by the     employee on <font color="blue">relatively</font> short notice</td>
    </tr>
    <tr>
      <td>The value to employees of stock-related     benefits that vest                                         36       _________________________________________________________________       over  time—such  as options and restricted stock—will be <font color="blue">significant</font>ly     <font color="blue">affected by movements</font> in our stock price that we <font color="blue">cannot control</font>, and may at     any point in time be insufficient to counteract more <font color="blue">lucrative offers from</font>     other companies</td>
    </tr>
    <tr>
      <td>We face intense <font color="blue">competition</font> for our <font color="blue">scientific personnel from</font> our     <font color="blue">competitors</font>, our <font color="blue">collaborator</font>s and other <font color="blue">companies throughout</font> our industry</td>
    </tr>
    <tr>
      <td>Moreover, the growth of local <font color="blue">bio<font color="blue">technology</font></font> companies and the expansion of     major  <font color="blue">pharmaceutical</font>  companies  into  the  Boston area has increased     <font color="blue">competition</font> for the <font color="blue">available pool</font> of skilled employees, especially in     <font color="blue">technical fields</font>, and the high cost of living in the <font color="blue">Boston and San Diego     </font>areas  makes it <font color="blue">difficult</font> to <font color="blue">attract employees from</font> other parts of the     country</td>
    </tr>
    <tr>
      <td>A  failure to retain, as well as hire, train and <font color="blue">effective</font>ly     <font color="blue">integrate into</font> our <font color="blue">organization</font> a sufficient number of qualified <font color="blue">scientists</font>     and <font color="blue">professionals would negatively impact</font> our business and our ability to     grow our business</td>
    </tr>
    <tr>
      <td>In addition, the level of <font color="blue">funding under certain</font> of our     <font color="blue">collaborative</font> <font color="blue">agreements</font> depends on the number of our <font color="blue">scientists</font> performing     <font color="blue">research under</font> those <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot hire</font> and retain the required     personnel, funding received under the <font color="blue">agreements</font> may be reduced</td>
    </tr>
    <tr>
      <td>IF  OUR  PATENTS DO NOT PROTECT OUR PRODUCTS, OR OUR PRODUCTS INFRINGE     THIRD-PARTY PATENTS, WE COULD BE SUBJECT TO LITIGATION AND SUBSTANTIAL     LIABILITIES                We have numerous patent <font color="blue">application</font>s pending in the <font color="blue">United States</font>,     <font color="blue">as well as foreign counterparts</font> in other countries</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>,     in <font color="blue">significant</font> part, on our ability to obtain and maintain <font color="blue">United States</font> and     foreign patent protection for our products, their uses and our processes, to     preserve our trade secrets and to operate <font color="blue">without infringing</font> the <font color="blue">proprietary</font>     rights of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We do not know whether any <font color="blue">patents will issue from</font>     any of our patent <font color="blue">application</font>s or, even if <font color="blue">patents issue</font> or have issued,     that the issued claims <font color="blue">will provide us with</font> any <font color="blue">significant</font> protection     <font color="blue">against competitive products</font> or otherwise be valuable <font color="blue">commercially</font></td>
    </tr>
    <tr>
      <td><font color="blue">Legal     </font>standards relating to the validity of patents and the proper scope of their     claims in the <font color="blue">pharmaceutical</font> field are <font color="blue">still evolving</font>, and there is no     <font color="blue">consistent</font>  law  or  policy  regarding  the <font color="blue">valid breadth</font> of claims in     bio<font color="blue">pharmaceutical</font> patents or the effect of <font color="blue">prior art on them</font></td>
    </tr>
    <tr>
      <td>If we are not     able  to  obtain  adequate  patent  protection, our ability to prevent     <font color="blue">competitors</font> from making, using and selling similar <font color="blue">products will</font> be limited</td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">activities</font> may infringe the claims of patents held by third     parties</td>
    </tr>
    <tr>
      <td>Defense and <font color="blue">prosecution</font> of infringement or other <font color="blue">intellectual</font>     property claims, as well as <font color="blue">participation</font> in other inter-party proceedings,     can  be expensive and time-consuming, regardless of whether or not the     outcome  is  favorable to us</td>
    </tr>
    <tr>
      <td>If the outcome of any <font color="blue">such litigation</font> or     proceeding were adverse, we could be subject to <font color="blue">significant</font> liabilities to     <font color="blue">third parties</font>, could be required to obtain licenses from <font color="blue">third parties</font> or     could be required to <font color="blue">cease sales</font> of <font color="blue">affected products</font>, any of <font color="blue">which outcomes</font>     could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>WE DO NOT KNOW WHETHER LEXIVA/TELZIR WILL CONTINUE TO BE COMPETITIVE IN THE     MARKET FOR HIV PIs OR IF BRECANAVIR, IF APPROVED, WILL BE SUCCESSFUL IN THE     MARKET                We currently receive <font color="blue">royalties from sales</font> of Lexiva/Telzir under our     <font color="blue">collaboration</font> with <font color="blue">GlaxoSmithKline </font>and will receive product royalty payments     on  sales  of  <font color="blue">brecanavir</font>, if any, if <font color="blue">brecanavir</font> is approved for sale</td>
    </tr>
    <tr>
      <td>Lexiva/Telzirapstas  share  of the <font color="blue">worldwide protease inhibitor market may</font>     <font color="blue">decrease due</font> to <font color="blue">competitive forces</font> and <font color="blue">market dynamics</font></td>
    </tr>
    <tr>
      <td><font color="blue">Other HIV PIs </font>and a     number  of  other  products,  including Viread® (tenofovir dispoproxil     fumerate), Sustiva® (<font color="blue">efavirenz</font>) and Ziagen® (<font color="blue">abacavir</font>) are on the market for     the  treatment  of  HIV  infection  and <font color="blue">AIDS Other </font>drugs are still in     <font color="blue">development</font> by our <font color="blue">competitors</font>, including Bristol-Myers Squibb, Boehringer     Ingelheim and Johnson &amp; Johnson, which may have better efficacy, fewer side     effects, easier <font color="blue">administration</font> and/or lower costs than Lexiva/Telzir or     <font color="blue">brecanavir</font></td>
    </tr>
    <tr>
      <td>Moreover, the growth in the <font color="blue">worldwide market</font> <font color="blue">for HIV PIs </font>has, to     a <font color="blue">certain extent</font>, occurred as a result of early and <font color="blue">aggressive treatment</font> of     HIV <font color="blue">infection with</font> a protease inhibitor-based regimen</td>
    </tr>
    <tr>
      <td>Changes in treatment     strategy, in <font color="blue">which treatment</font> is initiated later in the course of infection,     or in <font color="blue">which treatment</font> is more <font color="blue">often initiated with</font> a regimen that does not     include a protease inhibitor, may result in <font color="blue">reduced use</font> of HIV PIs</td>
    </tr>
    <tr>
      <td>As a     result, the total market <font color="blue">for HIV PIs </font>may decline,                                         37       _________________________________________________________________       <font color="blue">decreasing</font> the <font color="blue">sales potential</font> of Lexiva/Telzir and/or <font color="blue">brecanavir</font></td>
    </tr>
    <tr>
      <td>Further,     although  we  provide  <font color="blue">education</font>  efforts  related to the promotion of     Lexiva/Telzir  in  the  United  States  and  key  markets  in  Europe,     <font color="blue">GlaxoSmithKline </font>directs the majority of the marketing and <font color="blue">sales efforts</font> and     the positioning of Lexiva/Telzir in the <font color="blue">overall market</font>, and we have little     <font color="blue">control over</font> the direction or success of those efforts</td>
    </tr>
    <tr>
      <td><font color="blue">GlaxoSmithKline </font>has     the right to terminate its <font color="blue">agreement with us without</font> cause upon twelve     months &amp;apos  notice, and would have <font color="blue">no obligation</font> to <font color="blue">pay further royalties</font> to us     upon any such <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>IF PHYSICIANS, PATIENTS AND THIRD-PARTY PAYORS DO NOT ACCEPT OUR FUTURE     DRUGS, WE MAY BE UNABLE TO GENERATE SIGNIFICANT REVENUE, IF ANY                Even if our drug <font color="blue">candidates</font> obtain <font color="blue">regulatory</font> approval, they may not     gain <font color="blue">market acceptance</font> among physicians, patients and <font color="blue">health care payors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>may elect not to recommend our drugs for a variety of reasons     including:          •                 the timing of the <font color="blue">market <font color="blue">introduction</font></font> of <font color="blue">competitive drugs</font>;          •                 <font color="blue">lower <font color="blue">demonstrate</font>d clinical safety</font> and <font color="blue">efficacy compared</font> to                 other drugs;          •                 lack of cost-<font color="blue">effective</font>ness;          •                 lack of <font color="blue">availability</font> of <font color="blue">reimbursement</font> from third-party payors;          •                 convenience and ease of <font color="blue">administration</font>;          •                 prevalence and severity of adverse side effects;          •                 other <font color="blue">potential advantages</font> of <font color="blue">alternative treatment methods</font>; and          •                 in<font color="blue">effective</font> marketing and <font color="blue">distribution support</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">approved drugs fail</font> to achieve <font color="blue">market acceptance</font>, we would     not be able to generate <font color="blue">significant</font> revenue</td>
    </tr>
    <tr>
      <td>IF THE GOVERNMENT AND OTHER THIRD-PARTY PAYORS FAIL TO PROVIDE COVERAGE AND     ADEQUATE PAYMENT RATES FOR OUR FUTURE DRUGS, OUR REVENUE AND PROSPECTS FOR     PROFITABILITY WILL BE HARMED                In <font color="blue">both domestic</font> and <font color="blue">foreign markets</font>, our sales of any <font color="blue">future drugs</font>     will depend in part upon the <font color="blue">availability</font> of <font color="blue">reimbursement</font> from third-party     payors</td>
    </tr>
    <tr>
      <td>Such third-party payors include <font color="blue">government</font> health programs such as     Medicare,  managed  care  providers, private health insurers and other     <font color="blue"><font color="blue">organization</font>s</font></td>
    </tr>
    <tr>
      <td>These third-party payors are <font color="blue">increasingly attempting</font> to     contain  healthcare  <font color="blue">costs by demanding price <font color="blue">discounts</font></font> or rebates and     <font color="blue">limiting both</font> the types and variety of drugs that they will cover and the     amounts that they will pay for these drugs</td>
    </tr>
    <tr>
      <td>We might need to conduct     post-marketing studies in order to <font color="blue">demonstrate</font> the cost-<font color="blue">effective</font>ness of any     <font color="blue">future drugs</font> to such payors &amp;apos  <font color="blue">satisfaction</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">studies might</font> require us to     commit a <font color="blue">significant</font> amount of <font color="blue">management</font> time and financial and other     resources</td>
    </tr>
    <tr>
      <td>Our  future  drugs  might  not  ultimately  be  considered     cost-<font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>third-party <font color="blue">reimbursement</font> might not be available to     <font color="blue">enable us</font> to maintain <font color="blue">price levels sufficient</font> to realize an <font color="blue">appropriate</font>     return on <font color="blue">investment</font> in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>rates may vary according to the use of the drug and     the <font color="blue">clinical setting</font> in which it is used, may be <font color="blue">based on payments allowed</font>     for lower-cost products that are already reimbursed, may be <font color="blue">incorporated</font>     <font color="blue">into existing payments</font> for other products or services, and may reflect     budgetary constraints and/or imperfections in <font color="blue">Medicare or Medicaid </font>data used     to calculate these rates</td>
    </tr>
    <tr>
      <td>Net prices for drugs may be <font color="blue">reduced by mandatory</font>     <font color="blue">discounts</font>  or  rebates required by <font color="blue">government</font> health care programs</td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">legislation</font> has <font color="blue">been introduced</font> in <font color="blue">Congress </font>that, if enacted,     <font color="blue">would permit</font> more <font color="blue">widespread importation</font> of <font color="blue">drugs from</font> foreign countries     into the <font color="blue">United States</font>, which may include <font color="blue">importation from countries</font> where     the  drugs  are  sold  <font color="blue">at lower prices than</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">legislation</font>,  or similar <font color="blue">regulatory</font> changes or <font color="blue">relaxation</font> of laws that     <font color="blue">restrict imports</font> of <font color="blue">drugs from</font> other countries, could reduce the net price     we receive for our <font color="blue">marketed drugs</font></td>
    </tr>
    <tr>
      <td>38       _________________________________________________________________       RECENT FEDERAL LEGISLATION WILL INCREASE THE PRESSURE TO REDUCE PRICES OF     PHARMACEUTICAL PRODUCTS PAID FOR BY MEDICARE, WHICH COULD ADVERSELY AFFECT     OUR REVENUES, IF ANY                The Medicare Prescription Drug Improvement and Modernization Act of     2003, or MMA, changed the way Medicare will cover and pay for <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">legislation</font> expanded Medicare coverage for <font color="blue">drug purchases by</font>     the elderly and <font color="blue">eventually will introduce</font> a <font color="blue">new <font color="blue">reimbursement</font> methodology</font>     <font color="blue">based on average sales prices</font> for drugs</td>
    </tr>
    <tr>
      <td>In addition, this <font color="blue">legislation</font>     <font color="blue">provides authority</font> for limiting the number of drugs that will be covered in     any <font color="blue">therapeutic</font> class</td>
    </tr>
    <tr>
      <td>As a result of this <font color="blue">legislation</font> and the expansion of     <font color="blue">federal coverage</font> of <font color="blue">drug product</font>s, we expect that <font color="blue">there will</font> be <font color="blue">additional</font>     pressure to contain and <font color="blue">reduce costs</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">cost reduction initiatives</font> and     other provisions of this <font color="blue">legislation</font> could decrease the coverage and price     that we receive for any <font color="blue">approved products</font> and <font color="blue">could seriously harm</font> our     business</td>
    </tr>
    <tr>
      <td>While  the  MMA  <font color="blue">applies only</font> to <font color="blue">drug benefits</font> for <font color="blue">Medicare  </font>   beneficiaries, <font color="blue">private payors</font> often follow Medicare <font color="blue">coverage policy</font> and     payment  <font color="blue">limitations</font> in setting their own <font color="blue">reimbursement</font> rates, and any     reduction in <font color="blue">reimbursement</font> that results from the MMA may result in a similar     reduction in <font color="blue">payments from <font color="blue">private payors</font></font></td>
    </tr>
    <tr>
      <td>OUR BUSINESS HAS A SUBSTANTIAL RISK OF PRODUCT LIABILITY CLAIMS IF WE ARE     UNABLE TO OBTAIN APPROPRIATE LEVELS OF INSURANCE, A PRODUCT LIABILITY CLAIM     COULD ADVERSELY AFFECT OUR BUSINESS                Our business <font color="blue">exposes us</font> to <font color="blue">significant</font> potential product <font color="blue">liability</font>     risks that are inherent in the <font color="blue">development</font>, <font color="blue">manufacturing</font> and sales and     marketing of human <font color="blue">therapeutic</font> products</td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">clinical trial</font>     insurance and will seek to obtain <font color="blue"><font color="blue">product <font color="blue">liability</font> insurance</font> prior</font> to the     sales and marketing of any of our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>However, our insurance     may  not  provide  adequate  coverage  against  <font color="blue">potential liabilities</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">clinical trial</font> and <font color="blue">product <font color="blue">liability</font> insurance</font> is becoming     <font color="blue">increasingly expensive</font></td>
    </tr>
    <tr>
      <td>As a result, we may be unable to maintain current     amounts of insurance coverage or obtain <font color="blue">additional</font> or sufficient insurance     at a reasonable cost to protect against losses that could have a material     adverse effect on us</td>
    </tr>
    <tr>
      <td>If a claim is brought against us, we might be required     to pay legal and other expenses to defend the claim, <font color="blue">as well as uncovered</font>     <font color="blue">damages awards</font> resulting from a claim brought <font color="blue">successfully</font> against us</td>
    </tr>
    <tr>
      <td>Furthermore, whether or not we are <font color="blue">ultimately successful</font> in defending any     such  claims, we might be required to direct <font color="blue">significant</font> financial and     <font color="blue">managerial resources</font> to <font color="blue">such defense</font>, and <font color="blue">adverse publicity</font> is likely to     result</td>
    </tr>
    <tr>
      <td>IF WE DO NOT COMPLY WITH LAWS REGULATING THE PROTECTION OF THE ENVIRONMENT     AND HEALTH AND HUMAN SAFETY, OUR BUSINESS COULD BE ADVERSELY AFFECTED                Our research and <font color="blue">development</font> efforts involve the <font color="blue">controlled use</font> of     <font color="blue">hazardous materials</font>, chemicals and <font color="blue">various radioactive compounds</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we believe that our <font color="blue">safety procedures</font> for handling and disposing of these     materials  comply  with  the <font color="blue">standards prescribed by</font> state and federal     <font color="blue">regulations</font>, the risk of <font color="blue"><font color="blue">accident</font>al contamination</font> or <font color="blue">injury from</font> these     <font color="blue">materials cannot</font> be eliminated</td>
    </tr>
    <tr>
      <td>If an <font color="blue">accident</font> occurs, we could be held     liable  for resulting damages, <font color="blue">which could</font> be substantial</td>
    </tr>
    <tr>
      <td>We are also     subject to numerous environmental, health and <font color="blue">workplace safety laws</font> and     <font color="blue">regulations</font>, including those governing laboratory procedures, exposure to     blood-borne pathogens and the handling of <font color="blue">bio<font color="blue">hazardous materials</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we maintain workers &amp;apos  <font color="blue">compensation insurance</font> to cover us for costs we may     incur due to injuries to our employees resulting from the use of these     materials,  this  insurance  may not <font color="blue">provide adequate coverage against</font>     <font color="blue">potential liabilities</font></td>
    </tr>
    <tr>
      <td>Due to the small amount of <font color="blue">hazardous materials</font> that     we generate, we have determined that the cost to <font color="blue">secure insurance coverage</font>     for <font color="blue">environmental <font color="blue">liability</font></font> and <font color="blue">toxic tort</font> claims far exceeds the benefits</td>
    </tr>
    <tr>
      <td>Accordingly, we do not maintain any insurance to <font color="blue">cover pollution <font color="blue">conditions</font></font>     or other <font color="blue">extraordinary</font> or <font color="blue">unanticipated events</font> relating to our use and     disposal of <font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>federal, state and <font color="blue">local laws</font>     and <font color="blue">regulations</font> affecting our <font color="blue">operations</font> may be adopted in the future</td>
    </tr>
    <tr>
      <td>We     may  incur  substantial costs to <font color="blue">comply with</font>, and substantial fines or     penalties if we violate, any of these laws or <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>39       _________________________________________________________________       WE HAVE ADOPTED ANTI-TAKEOVER PROVISIONS THAT MAY FRUSTRATE ANY ATTEMPT TO     REMOVE OR REPLACE OUR CURRENT MANAGEMENT                Our <font color="blue">corporate charter</font> and by-law provisions and <font color="blue">stockholder rights</font>     plan <font color="blue">may discourage certain types</font> of <font color="blue">transactions involving</font> an actual or     potential change of control of Vertex that might be <font color="blue">beneficial</font> to us or our     <font color="blue">security holders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">charter provides</font> for <font color="blue">staggered terms</font> for the members     of  the <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>Our by-laws grant the <font color="blue">directors</font> a right to     <font color="blue">adjourn annual meetings</font> of <font color="blue">stockholders</font>, and <font color="blue">certain provisions</font> of the     by-laws may be <font color="blue">amended only with</font> an 80prca stockholder vote</td>
    </tr>
    <tr>
      <td>The <font color="blue">rights will</font> not <font color="blue">trade separately from</font>     the <font color="blue"><font color="blue">common stock</font> until</font>, and are <font color="blue">exercisable only upon</font>, the <font color="blue">acquisition</font> or     the potential <font color="blue">acquisition</font> through tender offer by a person or group of 15prca     or more of the <font color="blue">outstanding <font color="blue">common stock</font></font></td>
    </tr>
    <tr>
      <td>We may issue shares of any class or     series of <font color="blue">preferred stock</font> in the <font color="blue">future without stockholder approval</font> and     <font color="blue">upon such terms as</font> our <font color="blue">Board of Directors</font> may determine</td>
    </tr>
    <tr>
      <td>The rights of the     holders of <font color="blue"><font color="blue">common stock</font> will</font> be subject to, and may be <font color="blue">adversely</font> affected     by, the rights of the holders of any class or series of <font color="blue">preferred stock</font> that     may be issued in the future</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">stockholders</font> or other <font color="blue">parties may</font>     find it more <font color="blue">difficult</font> to remove or replace our current <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>OUR STOCK PRICE MAY FLUCTUATE BASED ON FACTORS BEYOND OUR CONTROL                Market prices for securities of <font color="blue">companies such as</font> Vertex are highly     volatile</td>
    </tr>
    <tr>
      <td>Within the twelve months ended <font color="blue">December </font>31, 2005, our <font color="blue">common stock</font>     traded between dlra8dtta61 and dlra29dtta24 per share</td>
    </tr>
    <tr>
      <td>The market for our stock, like     that of other companies in the <font color="blue">bio<font color="blue">technology</font></font> field, has from time to time     experienced <font color="blue">significant</font> price and <font color="blue">volume fluctuations</font> that are unrelated to     our operating performance</td>
    </tr>
    <tr>
      <td>The <font color="blue">future <font color="blue">market price</font></font> of our <font color="blue">securities could</font>     be <font color="blue">significant</font>ly and <font color="blue">adversely</font> affected by factors such as:          •                 <font color="blue">announcements</font> of results of <font color="blue"><font color="blue">clinical trial</font>s</font> or nonclinical                 studies;          •                 <font color="blue">announcements</font>  of  financial  results  and other operating                 <font color="blue">performance measures</font>, or capital structuring <font color="blue">activities</font>;          •                 <font color="blue">technological</font> innovations or the <font color="blue">introduction</font> of <font color="blue">new products</font> by                 our <font color="blue">competitors</font>;          •                 <font color="blue">government</font> <font color="blue">regulatory</font> action;          •                 public concern as to the safety of products developed by others;          •                 <font color="blue">development</font>s in patent or other <font color="blue"><font color="blue">intellectual</font> property</font> rights or                 <font color="blue">announcements</font> relating to these matters;          •                 <font color="blue">development</font>s in domestic and international <font color="blue"><font color="blue">government</font>al</font> policy                 or regulation, for example relating to <font color="blue"><font color="blue">intellectual</font> property</font>                 rights; and          •                 <font color="blue">development</font>s relating <font color="blue">specifically</font> to other companies and market                 <font color="blue">conditions</font>  for <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> stocks in                 general</td>
    </tr>
    <tr>
      <td>OUR OUTSTANDING INDEBTEDNESS MAY MAKE IT MORE DIFFICULT TO OBTAIN ADDITIONAL     FINANCING OR REDUCE OUR FLEXIBILITY TO ACT IN OUR BEST INTERESTS                As of <font color="blue">December </font>31, 2005, we had approximately dlra42dtta1 million in     aggregate <font color="blue">principal amount</font> of 5prca <font color="blue">Convertible Subordinated Notes </font>due in     <font color="blue">September </font>2007 ( &amp;quote 2007 Notes &amp;quote ) and approximately dlra118dtta0 million in aggregate     <font color="blue">principal amount</font> of 5dtta75prca <font color="blue">Convertible Senior Subordinated Notes </font>due in     <font color="blue">February </font>2011 ( &amp;quote 2011 Notes &amp;quote ) outstanding</td>
    </tr>
    <tr>
      <td>The <font color="blue">high level</font> of our indebtedness     <font color="blue">will affect us by</font>:          •                 <font color="blue">exposing us</font> to fixed rates of interest, which may be in excess                 of <font color="blue">prevailing market rates</font>;          •                 making it more <font color="blue">difficult</font> to obtain <font color="blue">additional</font> financing for                 working capital, capital <font color="blue">expenditures</font>, debt service <font color="blue">requirements</font>                 or other purposes;                                         40       _________________________________________________________________       •            <font color="blue">constraining</font> our ability to <font color="blue">react quickly</font> in an <font color="blue">unfavorable economic</font>            climate or to changes in our business or the <font color="blue">pharmaceutical</font> industry;            and     •            requiring the <font color="blue">dedication</font> of a substantial portion of our expected            <font color="blue">cash flow</font> to service of our indebtedness, thereby reducing the amount            of expected <font color="blue">cash flow</font> available for other purposes</td>
    </tr>
    <tr>
      <td>Under the     lease, we are required to complete certain build-outs and <font color="blue">improvements</font> of     the <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We currently expect to occupy approximately 120cmam000 square     feet  of  the <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We have sublease <font color="blue">arrangements</font> in place for the     remaining  <font color="blue">rentable square footage</font> of the <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In determining our     <font color="blue">obligations</font> under the lease for the portion of the <font color="blue">facility</font> that we do not     expect to occupy, we have made <font color="blue">certain assumptions</font> relating to the costs     that will be incurred to satisfy our build-out <font color="blue">commitments under</font> the lease,     operating  costs,  the  time <font color="blue">necessary</font> to sublease the space after the     expiration of the <font color="blue">initial subleases</font>, projected <font color="blue">future sublease rental rates</font>     and  the anticipated durations of <font color="blue">future subleases</font></td>
    </tr>
    <tr>
      <td>Our estimates have     changed in the past, and may change in the future, resulting in <font color="blue">additional</font>     <font color="blue">adjustments</font>  to  the estimate of <font color="blue">liability</font>, and the effect of any such     <font color="blue">adjustments</font> could be material</td>
    </tr>
    <tr>
      <td>GOVERNMENT INVESTIGATIONS OR LITIGATION AGAINST OUR COLLABORATORS COULD     IMPACT OUR BUSINESS                The federal <font color="blue">government</font>, certain state <font color="blue">government</font>s and <font color="blue">private payors</font>     are  <font color="blue">investigating</font>  and  have  begun  to <font color="blue">file actions against numerous</font>     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies alleging that the reporting of     prices for <font color="blue">pharmaceutical</font> products has resulted in a false and overstated     Average Wholesale Price, or AWP, which in turn is alleged to have <font color="blue">improperly</font>     inflated the <font color="blue">reimbursement</font> paid by Medicare beneficiaries, insurers, state     Medicaid programs, medical plans and others to <font color="blue">health care providers</font> who     prescribed and <font color="blue">administered</font> those products</td>
    </tr>
    <tr>
      <td>Some payors are also alleging     that <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies are not reporting their      &amp;quote best price &amp;quote  to the states under the Medicaid program</td>
    </tr>
    <tr>
      <td>In addition, recent     <font color="blue">government</font>  litigation against <font color="blue">pharmaceutical</font> companies has <font color="blue">focused on</font>     <font color="blue">allegations</font> of off-label promotion in <font color="blue">connection with</font> the filing of false     claims for <font color="blue">government</font> <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td><font color="blue">In any AWP </font>cases or other <font color="blue">cases brought</font>     by  the  <font color="blue">government</font>  where our <font color="blue">collaborator</font>s or licensees are named as     <font color="blue">defendants with respect</font> to any <font color="blue">products licensed from us</font>, the outcome of the     <font color="blue">case could</font> have a material adverse effect on our financial results</td>
    </tr>
    <tr>
      <td>SALES OF ADDITIONAL SHARES OF OUR COMMON STOCK COULD CAUSE THE PRICE OF OUR     COMMON STOCK TO DECLINE                Sales of substantial amounts of our <font color="blue">common stock</font> in the <font color="blue">open market</font>,     or the <font color="blue">availability</font> of such shares for sale, could <font color="blue">adversely</font> affect the     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, the issuance of <font color="blue">common stock</font> upon     exercise  of  any  outstanding  option or the <font color="blue">conversion</font> of any of our     <font color="blue">outstanding convertible debt would</font> be dilutive, and may cause the market     price for a share of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005,     we had 108cmam153cmam000 shares of <font color="blue">common stock</font> issued and outstanding</td>
    </tr>
    <tr>
      <td>We also     had <font color="blue">outstanding options</font> to purchase approximately 14cmam669cmam000 shares of     common  <font color="blue">stock with exercise prices as set forth</font> in Note N,  &amp;quote Common and     Preferred Stock, &amp;quote  to our <font color="blue">consolidated financial statements</font> included in this     <font color="blue">Annual Report </font>on Form 10-K, and with a <font color="blue">weighted average exercise price</font> of     dlra22dtta84 per share</td>
    </tr>
    <tr>
      <td>Our outstanding notes were <font color="blue">convertible into approximately</font>     8cmam354cmam000 shares of <font color="blue">common stock</font> with a weighted average <font color="blue">conversion</font> price of     dlra19dtta16 per share</td>
    </tr>
    <tr>
      <td><font color="blue">Outstanding </font>options and convertible notes may be exercised     or converted, as the case may be, if the <font color="blue">market price</font> of our <font color="blue">common stock</font>     exceeds the <font color="blue">applicable exercise</font> or <font color="blue">conversion</font> price</td>
    </tr>
  </tbody>
</table>